Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free HTGMQ Stock Alerts

HTG Molecular Diagnostics (HTGMQ) Competitors

Compare

HTGMQ vs. PRENW, SMAPW, TT, KEYS, and TER

Should you buy HTG Molecular Diagnostics stock or one of its competitors? MarketBeat compares HTG Molecular Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HTG Molecular Diagnostics include Prenetics Global (PRENW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), and Teradyne (TER). These companies are all part of the "measuring and control equipment" industry.

How does HTG Molecular Diagnostics compare to Prenetics Global?

Prenetics Global (NASDAQ:PRENW) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Prenetics Global has higher revenue and earnings than HTG Molecular Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prenetics Global$120.07MN/AN/AN/AN/A
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A

Company Net Margins Return on Equity Return on Assets
Prenetics GlobalN/A N/A N/A
HTG Molecular Diagnostics N/A N/A N/A

In the previous week, Prenetics Global had 2 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 2 mentions for Prenetics Global and 0 mentions for HTG Molecular Diagnostics. Prenetics Global's average media sentiment score of 0.43 beat HTG Molecular Diagnostics' score of 0.00 indicating that Prenetics Global is being referred to more favorably in the media.

Company Overall Sentiment
Prenetics Global Neutral
HTG Molecular Diagnostics Neutral

Summary

Prenetics Global beats HTG Molecular Diagnostics on 3 of the 3 factors compared between the two stocks.

How does HTG Molecular Diagnostics compare to SportsMap Tech Acquisition?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and SportsMap Tech Acquisition (NASDAQ:SMAPW) are both measuring and control equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled SportsMap Tech Acquisition'saverage media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
SportsMap Tech Acquisition Neutral

SportsMap Tech Acquisition has lower revenue, but higher earnings than HTG Molecular Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
SportsMap Tech AcquisitionN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
SportsMap Tech Acquisition N/A N/A N/A

Summary

HTG Molecular Diagnostics beats SportsMap Tech Acquisition on 1 of the 1 factors compared between the two stocks.

How does HTG Molecular Diagnostics compare to Trane Technologies?

Trane Technologies (NYSE:TT) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Trane Technologies has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Trane Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trane Technologies$21.32B4.99$2.92B$12.9337.21
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A

In the previous week, Trane Technologies had 24 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 24 mentions for Trane Technologies and 0 mentions for HTG Molecular Diagnostics. Trane Technologies' average media sentiment score of 1.34 beat HTG Molecular Diagnostics' score of 0.00 indicating that Trane Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Trane Technologies Positive
HTG Molecular Diagnostics Neutral

83.0% of Trane Technologies shares are held by institutional investors. 0.4% of Trane Technologies shares are held by insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Trane Technologies presently has a consensus target price of $516.67, indicating a potential upside of 7.40%. Given Trane Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Trane Technologies is more favorable than HTG Molecular Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trane Technologies
1 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.76
HTG Molecular Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Trane Technologies has a net margin of 13.41% compared to HTG Molecular Diagnostics' net margin of 0.00%. Trane Technologies' return on equity of 35.55% beat HTG Molecular Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trane Technologies13.41% 35.55% 13.73%
HTG Molecular Diagnostics N/A N/A N/A

Trane Technologies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, HTG Molecular Diagnostics has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market.

Summary

Trane Technologies beats HTG Molecular Diagnostics on 14 of the 16 factors compared between the two stocks.

How does HTG Molecular Diagnostics compare to Keysight Technologies?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Keysight Technologies (NYSE:KEYS) are both measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Keysight Technologies has a consensus price target of $371.92, suggesting a potential upside of 16.51%. Given Keysight Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Keysight Technologies is more favorable than HTG Molecular Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HTG Molecular Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Keysight Technologies
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.86

Keysight Technologies has a net margin of 17.25% compared to HTG Molecular Diagnostics' net margin of 0.00%. Keysight Technologies' return on equity of 21.58% beat HTG Molecular Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Keysight Technologies 17.25%21.58%11.51%

84.6% of Keysight Technologies shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 0.4% of Keysight Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Keysight Technologies had 25 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 25 mentions for Keysight Technologies and 0 mentions for HTG Molecular Diagnostics. Keysight Technologies' average media sentiment score of 1.37 beat HTG Molecular Diagnostics' score of 0.00 indicating that Keysight Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Keysight Technologies Positive

HTG Molecular Diagnostics has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market. Comparatively, Keysight Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Keysight Technologies has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Keysight Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
Keysight Technologies$5.38B10.15$850M$6.0852.50

Summary

Keysight Technologies beats HTG Molecular Diagnostics on 14 of the 16 factors compared between the two stocks.

How does HTG Molecular Diagnostics compare to Teradyne?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Teradyne (NASDAQ:TER) are both measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Teradyne has a consensus price target of $394.53, suggesting a potential upside of 12.75%. Given Teradyne's stronger consensus rating and higher possible upside, analysts plainly believe Teradyne is more favorable than HTG Molecular Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HTG Molecular Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Teradyne
0 Sell rating(s)
4 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.81

Teradyne has a net margin of 22.55% compared to HTG Molecular Diagnostics' net margin of 0.00%. Teradyne's return on equity of 31.79% beat HTG Molecular Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Teradyne 22.55%31.79%22.36%

99.8% of Teradyne shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 0.2% of Teradyne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Teradyne had 36 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 36 mentions for Teradyne and 0 mentions for HTG Molecular Diagnostics. Teradyne's average media sentiment score of 1.12 beat HTG Molecular Diagnostics' score of 0.00 indicating that Teradyne is being referred to more favorably in the news media.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Teradyne Positive

HTG Molecular Diagnostics has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market. Comparatively, Teradyne has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Teradyne has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Teradyne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
Teradyne$3.19B17.17$554.05M$5.4064.80

Summary

Teradyne beats HTG Molecular Diagnostics on 14 of the 16 factors compared between the two stocks.

Get HTG Molecular Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HTGMQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HTGMQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HTGMQ vs. The Competition

Export
MetricHTG Molecular DiagnosticsAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2K$7.06B$12.20B
Dividend YieldN/AN/A2.67%9.41%
P/E Ratio0.00N/A27.1423.62
Price / SalesN/A0.00523.8189.60
Price / CashN/AN/A49.8158.78
Price / BookN/A0.0110.286.01
Net Income-$21.59M-$47.72M$3.60B$331.99M

HTG Molecular Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
PRENW
Prenetics Global
N/A$0.02
flat		N/A-63.6%$0.00$120.07MN/A1
SMAPW
SportsMap Tech Acquisition
N/A$0.03
flat		N/A-17.4%$0.00N/AN/AN/A
TT
Trane Technologies
4.4625 of 5 stars		$475.00
-1.1%		$516.67
+8.8%		+4.1%$106.15B$21.32B36.7444,000
KEYS
Keysight Technologies
4.5429 of 5 stars		$312.60
-3.1%		$371.92
+19.0%		+92.6%$55.15B$5.38B51.4116,800

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HTGMQ) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel